scaffold protein involved in DNA repairGenealiases: KIAA0146 · ODG9
Q-omics provides the consensus-scored SPIDR profile across patient tissues and cancer cell-line models. SPIDR expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SPIDR is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, SPIDR RNA expression shows 20,074 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KICH, and ACC as cancer lineages where SPIDR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPIDR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPIDR survival associations across molecular data types. SPIDR RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPIDR RNA expression–survival associations across cancer types. High SPIDR expression shows unfavorable associations in UVM, KICH, LGG and KIRP, but favorable associations in UCS and SKCM. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UVM as the clearest survival context for SPIDR RNA expression.
This table summarizes SPIDR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SPIDR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPIDR shows lower tumor expression in KICH, THCA and LUAD and higher tumor expression in COAD, CHOL and HNSC. The KICH box plot shows higher SPIDR RNA expression in normal versus tumor tissue (log2 FC = −1.705, t-test p < 0.001).
This table shows molecular features associated with SPIDR in patient tissues and cancer cell lines. In patient samples, SPIDR shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SPIDR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
